JW Jungwoo Hosts Launch Symposium for Hemlibra, a Hemophilia A Treatment

JW Pharmaceutical announced on the 13th that it held a two-day launch symposium for the type A hemophilia treatment 'Hemlibra' starting from the 7th.

JW Pharmaceutical held a launch symposium for the type A hemophilia treatment 'Hemlibra' over two days starting from the 7th at the 'Hotel Naru Seoul - M Gallery' located in Mapo-gu, Seoul.
[Photo by JW Pharmaceutical]

Hemlibra is a routine prophylactic agent for type A hemophilia caused by factor VIII deficiency in blood coagulation. It is a new drug applying bispecific antibody technology that simultaneously binds to factor IX and factor X. Among type A hemophilia treatments, it is the only one that can be used not only for patients with antibodies resistant to the existing factor VIII products but also for non-antibody patients, with preventive effects lasting up to once every four weeks via subcutaneous injection. In May, Hemlibra's health insurance coverage was expanded to include non-antibody severe type A hemophilia patients aged one year and older.

The symposium, held at Hotel Naru Seoul - M Gallery in Mapo-gu, Seoul, was conducted under the theme "Hemlibra and the Paradigm Shift in Type A Hemophilia Treatment" for domestic medical professionals related to hemophilia.

On the first day, the 7th, Professor Gary Dolan of St. Thomas' Hospital in the UK, a hemophilia treatment authority and former president of the UK Haemophilia Centre Doctors' Organisation (UKHCDO), shared cases of Hemlibra treatment for non-antibody type A hemophilia and various patient groups. Professor Dolan stated, "In the UK, since the expansion of coverage to non-antibody patients in 2019, 70-80% of patients at major hemophilia specialist centers switched to Hemlibra over two years," adding, "The standard treatment for hemophilia has shifted to Hemlibra."

Following this, Atsushi Muto, Head of New Drug Development at Japan's Chugai Pharmaceutical, the developer of Hemlibra, presented on the background of Hemlibra's development and its mechanism of action. The session chair, Chul-Joo Yoo, president of the Korean Society of Hematology and professor of pediatrics at Severance Hospital, shared, "In actual clinical settings, we have experienced sufficient efficacy with dosing once every four weeks," and emphasized, "Especially, the convenience of subcutaneous administration rather than intravenous injection is excellent."

On the 8th, Professor Seung-Min Han of Severance Hospital and Professor Young-Sil Park of Kangdong Kyung Hee University Hospital introduced new clinical data on Hemlibra and domestic patient treatment cases. The chair for the second day, Hyerim Jung, president of the Korean Society of Pediatric Hematology-Oncology and professor of pediatrics at Kangbuk Samsung Hospital, explained, "Existing treatments have limitations such as intravenous injections and frequent dosing, but Hemlibra can benefit pediatric patients with subcutaneous injections once every four weeks."

JW Pharmaceutical plans to strengthen marketing efforts to establish Hemlibra as the representative treatment for type A hemophilia. A company official stated, "Hemlibra, with its excellent dosing convenience and efficacy, will change the paradigm of the domestic hemophilia treatment market as a new treatment option," and added, "We hope Hemlibra will improve the quality of life for many more patients."

JW Pharmaceutical held a launch symposium for the type A hemophilia treatment "Hemlibra" over two days starting from the 7th at the "Hotel Naru Seoul - M Gallery" located in Mapo-gu, Seoul. Professor Gary Dolan from St Thomas' Hospital in the UK explained the use of Hemlibra for non-inhibitor type A hemophilia treatment and various patient case studies.
[Photo by JW Pharmaceutical]

This content was produced with the assistance of AI translation services.